

JAK2 V617F and *MPL* W515L/K Mutations in Korean Patients with Essential Thrombocythemia

Hee-Jung Kim, M.D.¹, Ja-Hyun Jang, M.D.¹, Eun-Hyung Yoo, M.D.¹, Hee-Jin Kim, M.D.^{1,2}, Chang-Seok Ki, M.D.¹, Jong-Won Kim, M.D.¹, and Sun-Hee Kim, M.D.¹

Department of Laboratory Medicine¹ and Genetics and Cardiovascular Center², Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

JAK2 V617F and *MPL* W515L/K mutations have been reported in approximately 50% and 5% of the patients with essential thrombocythemia (ET), respectively. We investigated the frequency of *MPL* W515L/K mutations in a series of consecutive patients with ET and post-essential thrombocythemia myelofibrosis (post-ET MF). The study subjects were 63 patients diagnosed either with ET (N=59) or post-ET MF (N=4) at our institution between June 2006 and February 2010. Among them, 35 (55.6%) had the *JAK2* V617F mutation. *MPL* W515L/K mutations were detected by direct sequencing analyses of exon 10, and 2 patients were found to harbor the following *MPL* mutations: W515L in 1 patient with ET and W515K in 1 patient with post-ET MF. Neither of the patients had the *JAK2* V617F mutation. The frequencies of the *MPL* W515L/K and *JAK2* V617F-negative mutations in our subjects with ET/post-ET MF were 3.2% (2/63) and 7.1% (2/28), respectively. This is the first study to report the frequency of *JAK2* V617F and *MPL* W515L/K mutations in Korean patients with ET/post-ET MF. (*Korean J Lab Med* 2010;30:474-6)

Key Words : *Essential thrombocythemia, mutation, JAK2, MPL, Korea*

The recently reported gain of function mutations in signal transduction molecules has remarkably increased our knowledge about the molecular genetics of myeloproliferative neoplasms (MPN) [1]. *JAK2* mutations occur in most patients with polycythemia vera (PV) and in about half of the patients with essential thrombocythemia (ET) [2]. Missense mutations in the *MPL* gene, which encodes the thrombopoietin receptor MIM 159530 have also been

reported in a small proportion (19%) of patients with ET and primary myelofibrosis [3-6]. *MPL* mutations usually affect the W515 residue in exon 10 [3, 7]. We investigated the frequency of *MPL* W515L/K mutations in a series of consecutive patients with ET and post-essential thrombocythemia myelofibrosis (post-ET MF).

The study subjects were 63 patients diagnosed either with ET (N=59) or post-ET MF (N=4) at our institution between June 2006 and February 2010. Among them, 35 patients (55.6%) had the *JAK2* V617F mutation, which was identified by allele-specific PCR and direct sequencing analyses. *MPL* W515L/K mutations were detected by direct sequencing analyses of exon 10. As a result, two patients were found to harbor the following *MPL* mutations: W515L mutation in 1 patient with ET (Patient 1) and W515K mutation, 1 patient with post-ET MF (Patient 2). Neither of the patients had the *JAK2* V617F mutation. The

Received : March 6, 2010
Revision received : May 3, 2010
Accepted : July 12, 2010

Manuscript No : KJLM10-043

Corresponding author : Hee-Jin Kim, M.D.

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea
Tel : +82-2-3410-2702, Fax : +82-2-3410-2719
E-mail : heejinkim@skku.edu

*This study was supported by the Samsung Medical Center Clinical Research Development Program grant, #CRS-106-56-2.

ISSN 1598-6535 ©The Korean Society for Laboratory Medicine

clinical and laboratory history of the 2 patients with the *MPL* W515L/K mutation was as follows.

Patient 1 was a 71-yr-old Korean woman and was admitted to our institution with a 5-month history of sustained thrombocytosis. Complete blood count (CBC) test performed on admission revealed the following results: Hb, 10.9 g/dL; white blood cells (WBC), $4.9 \times 10^9/L$; and platelets, $580 \times 10^9/L$. She did not have a family history of hematological disorders, including MPN. Clinically, she did not have a history of vascular events or other manifestations relevant to MPN. The bone marrow (BM) study showed hypercellular marrow with increased megakaryocytes with large and atypical morphology. Molecular-genetic analyses were performed on the patient's DNA samples from peripheral blood to detect *JAK2* V617F and exon 12 mutations, both of which were negative. On suspicion of ET, we additionally performed direct sequencing of exon 10 of the *MPL* gene on the patient's DNA samples from the BM aspirate. As a result, we detected the heterozygous *MPL* W515L mutation with a 50% mutant allele burden (Fig. 1). Finally, the patient was diagnosed with ET according to the WHO 2008 criteria [8]. She has been on routine follow-up for 3 months with aspirin medication.

Patient 2 was a 53-yr-old man with a history of ET




Fig. 1. *MPL* gene mutations in 2 Korean patients with myeloproliferative neoplasms. Patient 1 with essential thrombocythemia (ET) had the W515L mutation from c.1544G>T with an allele burden of approximately 50%. Patient 2 with post-ET myelofibrosis had W515K from c.1543_1544TG>AA with an allele burden of approximately 100% (homozygous).

for 12 yr. Due to progressive splenomegaly and anemia, a BM study was performed, which revealed extensive myelofibrosis and markedly decreased normal trilineage hematopoiesis. His CBC was as follows: Hb, 10.8 g/dL; WBC, $14.9 \times 10^9/L$; and platelets, $170 \times 10^9/L$. *JAK2* V617F and exon 12 mutations were negative on direct sequencing using his BM aspirate sample. The subsequent test for *MPL* mutations revealed a homozygous W515K mutation with a mutant allele burden ~100% (Fig. 1). Considering the patient's past medical history of ET and the BM findings of myelofibrosis by reticulin and Masson-Trichrome stains on the biopsy section, he was diagnosed with post-ET MF. He received unrelated allogeneic peripheral blood stem cell transplantation. He has been on routine outpatient follow-up for 2 yr post-transplant.

The data from this study showed that the frequency of the *MPL* W515L/K mutation in Korean patients with ET/post-ET MF was 3.2% (2/63) and that of *JAK2* V617F-negative ET/post-ET MF was 7.1% (2/28). The *MPL* mutation observed in patient 1 was a G-to-T transversion at nucleotide 1544 (c.1544G>T) replacing tryptophan with leucine at codon 515 (p.W515L) with a ~50% allele burden. Patient 2 had c.1543_1544TG>AA replacing the TGG codon for tryptophan with AAG for lysine (p.W515K) with a ~100% allele burden (homozygous). W515L and W515K are the 2 most frequent *MPL* mutations in ET, each accounting for 60–75% and 16–40%, respectively [3, 6, 7]. Unlike MPN with *JAK2* mutations, only limited studies have been reported on genotype-phenotype correlations in *MPL* mutations [3, 5, 6]. As for the type of the mutation, while the W515L mutation is consistently from c.1544G>T, 2 different mutations have been reported to cause W515K, c.1543_1544TG>AA and c.1543_1545TGG>AAA [3]. Interestingly, c.1543_1544TG>AA was reported in patients with both ET and idiopathic myelofibrosis (IMF), while c.1543_1545TGG>AAA was described only in IMF [3]. As for the mutant allele burden, W515K was reported more frequently to be homozygous than W515L, particularly in ET [3–6]. Lastly, a significantly younger age at onset was reported in W515K than in W515L, although controversies still exist on this correlation [3, 6]. In our 2 Kore-

an patients, patient 1 with W515L had early-phase ET at 71 yr of age with a ~50% mutant allele burden, while patient 2 with W515K from c.1543_1544TG>AA had been diagnosed with ET at the age of 41 and experienced progression into post-ET MF with a ~100% mutant burden (homozygous). Our findings, albeit only from 2 patients, are in line with the aforementioned genotype-phenotype correlations from previous studies. The relatively young age at onset, progression to myelofibrosis, and high mutant allele burden in patient 2 might suggest that W515K from 1543_1544TG>AA is more aggressive than W515L. It was unfortunate that we could not determine the *MPL* mutation status of patient 2 at his early manifestation of ET.

To the best of our knowledge, this is the first study to report the frequency of *JAK2* V617F and *MPL* W515L/K mutations in Korean patients with ET/post-ET MF. In addition to the *JAK2* mutations, the *MPL* gene mutation status should be determined in patients suspected of having MPN. Data from more patients and comprehensive analyses are required to reveal the frequency of *MPL* mutations and genotype-phenotype correlations in MPN in Korean patients.

REFERENCES

1. Kilpivaara O and Levine RL. *JAK2* and *MPL* mutations in myeloproliferative neoplasms: discovery and science. *Leukemia* 2008; 22:1813-7.
2. Kralovics R. Genetic complexity of myeloproliferative neoplasms. *Leukemia* 2008;22:1841-8.
3. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. *MPL* mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood* 2008;112:141-9.
4. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. *MPL*515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood* 2006;108:3472-6.
5. Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D, et al. Characterization of 35 new cases with four different *MPL*W515 mutations and essential thrombocytosis or primary myelofibrosis. *Haematologica* 2009;94:141-4.
6. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of *MPL* 515W>L/K mutation in essential thrombocythemia. *Blood* 2008;112: 844-7.
7. Boyd EM, Bench AJ, Goday-Fernandez A, Anand S, Vaghela KJ, Beer P, et al. Clinical utility of routine *MPL* exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. *Br J Haematol* 2010;149:250-7.
8. Thiele J, Kvasnicka HM, et al. Essential thrombocythaemia. In: Swerdlow SH, Campo E, et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press, 2008:48-50.